Search | Caixin

di ning

In Depth: Why China’s Drug-Review Revamp Is Stalling

Budget constraints and loss of talent are hobbling China’s top drug evaluation agency, fueling industry
In Depth: Domestic Medical-Device Startups Struggling To Cut Through

Domestic startups angling for a piece of China’s high-end medical-device market are struggling to break
Chinese Medical Device Startups Face Tough Market

Domestic startups angling for a piece of China’s booming medical device market are struggling to break
Money-Losing Vaccine Maker Aims to Soothe Skeptics With Hong Kong IPO

Biotech firm CanSino Biologics Inc. will become China’s first money-losing vaccine maker to list in
Social Issues Under Spotlight at China’s ‘Two Sessions’

As thousands of Chinese lawmakers and political advisers descend on Beijing for the country’s biggest
Chinese Biotech Firm Aims to Beat Foreign Rivals on Price With New Cancer Drug

CEO Li Ning told Caixin on Thursday. Merck’s Keytruda goes for about 300,000 yuan ($43,600) per
He Jiankui Used AIDS Network to Recruit 200 Couples for Gene-Editing Experiment

As the world reels from the revelation that the first gene-edited humans may have been born in China
Investigation Launched Into Baby DNA Editing Claims

ethical review committee of the institution involved. Zhang Di of Peking Union Medical College, who has
Baby Gene-Editing Breakthrough Claim Slammed

also banned by a Chinese regulation on reproductive technology, said Zhang Di, a bioethics researcher
Chinese Vaccine-Maker Fined $1.3 Billion After Scandal

Chinese rabies vaccine-maker Changchun Changsheng Life Sciences Ltd. was fined more than 9.1 billion